KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Capital Expenditures (2017 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Capital Expenditures for 9 consecutive years, with $142.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures rose 10.08% year-over-year to $142.0 million, compared with a TTM value of $501.0 million through Dec 2025, up 0.6%, and an annual FY2025 reading of $501.0 million, up 0.6% over the prior year.
  • Capital Expenditures was $142.0 million for Q4 2025 at Teva Pharmaceutical Industries, up from $136.0 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $157.0 million in Q1 2022 and bottomed at $96.0 million in Q2 2025.
  • Average Capital Expenditures over 5 years is $131.8 million, with a median of $132.5 million recorded in 2024.
  • The sharpest move saw Capital Expenditures increased 22.13% in 2023, then dropped 18.49% in 2024.
  • Year by year, Capital Expenditures stood at $153.0 million in 2021, then fell by 7.19% to $142.0 million in 2022, then decreased by 16.2% to $119.0 million in 2023, then rose by 8.4% to $129.0 million in 2024, then increased by 10.08% to $142.0 million in 2025.
  • Business Quant data shows Capital Expenditures for TEVA at $142.0 million in Q4 2025, $136.0 million in Q3 2025, and $96.0 million in Q2 2025.